OKUR · OnKure Therapeutics, Inc.
$3.63
-0.17 (-4.35%)
At close · Aug 31
Going-concern doubt
— cleared Aug 4, 2026
The latest filing states the doubt was alleviated.
“As of December 31, 2025, the Company had determined that substantial doubt about the Company's ability to continue as a going concern for a period of at least 12 months from the date of the issuance of those financial statements did exist. However, following completion of the 2026 Private Placement (see Note 9), management believes the Company's cash, cash equivalents and marketable securities will be sufficient to fund its current operating plan for at least the next 12 months from the date of issuance of these condensed consolidated financial statements and as such substantial doubt has been alleviated.”View the 10-Q filed Aug 4, 2026
Market Cap
$153.48M
Shares
40.50M
Fails to deliver — shares from a trade that were not delivered to the buyer by the settlement date — published by the SEC twice a month. Persistent fails can reflect settlement problems or naked short selling.
Fails to Deliver History
| Settlement Date | Quantity | Price | Value |
|---|---|---|---|
| 2026-08-11 | 557 | $4.06 | $2,261 |
| 2026-08-05 | 2,984 | $4.10 | $12,234 |
| 2026-06-24 | 45 | $4.20 | $189 |
| 2026-06-23 | 625 | $4.44 | $2,775 |
| 2026-06-22 | 1,322 | $4.48 | $5,923 |
| 2026-06-15 | 232 | $4.20 | $974 |
| 2026-06-05 | 553 | $4.30 | $2,378 |
Showing 1–7 of 7 settlements
Key facts
CIK
1637715
CUSIP
68277Q105
13F (30d)
73 filings
71 filers
Visit website
Investor relations